An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan Plus Low-Dose Gemcitabine Versus Placebo Plus Low-Dose Gemcitabine in Patients With Metastatic (Stage IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments (PANCRIT-1)

The is a double-blind, randomized phase 3 study of 90Y-clivatuzumab tetraxetan with low-dose gemcitabine, versus placebo and low-dose gemcitabine in metastatic pancreatic cancer patients who have progressed on at least 2 prior therapies for metastatic cancer (1 of which was a gemcitabine-containing regimen).

开始日期2013-12-01

申办/合作机构

Gilead Sciences, Inc.

NCT01510561

/ Withdrawn临床1期

A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

90Y-hPAM4 is administered weekly for 3 weeks combined with 4 weekly doses of gemcitabine to assess. This is a dose escalation study of 90Y-hPAM4 to assess which dose is safe and effective as 3rd line treatment for patients with metastatic pancreatic cancer. Patients are then followed weekly for 12 weeks and afterwards for up to 1 year.

开始日期2012-03-01

申办/合作机构

Gilead Sciences, Inc.

NCT00603863

/ Completed临床1/2期

A Phase Ib/II Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Patients With Previously Untreated Advanced Pancreatic Cancer.

This is a study to test whether different doses of 90Y-hPAM4 are safe to give in combination with gemcitabine in patients with previously untreated pancreatic cancer.

开始日期2008-01-01

申办/合作机构

Gilead Sciences, Inc.

100 项与 90Y Clivatuzumab Tetraxetan 相关的临床结果

登录后查看更多信息

100 项与 90Y Clivatuzumab Tetraxetan 相关的转化医学

登录后查看更多信息

100 项与 90Y Clivatuzumab Tetraxetan 相关的专利（医药）

登录后查看更多信息

项与 90Y Clivatuzumab Tetraxetan 相关的文献（医药）

2015-09-01·European journal of cancer (Oxford, England : 1990)1区 · 医学

90 Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies

1区 · 医学

Article

作者: O'Neil, Bert H ; Wegener, William A ; Mitchel, Edith P ; Horne, Heather ; Richards, Donald A ; Pandit-Taskar, Neeta ; Sharkey, Robert M ; Gribbin, Thomas E ; Von Hoff, Daniel D ; Braiteh, Fadi S ; Ocean, Allyson J ; O'Reilly, Eileen M ; Frank, Richard C ; Guarino, Michael J ; Cohen, Steven J ; Lowery, Maeve A ; Ramanathan, Ramesh K ; Lee, Fa-Chyi ; Dragovich, Tomislav ; Manzone, Timothy C ; Conkling, Paul R ; Intenzo, Charles M ; Bridges, Benjamin B ; Picozzi, Vincent J ; Starodub, Alexander N ; Lee, Marie ; Bahary, Nathan ; Goldsmith, Stanley J ; Sheikh, Arif ; Goldenberg, David M ; Korn, Ronald L

BACKGROUND:

For patients with metastatic pancreatic adenocarcinoma, there are no approved or established treatments beyond the 2nd line. A Phase Ib study of fractionated radioimmunotherapy was undertaken in this setting, administering (90)Y-clivatuzumab tetraxetan (yttrium-90-radiolabelled humanised antibody targeting pancreatic adenocarcinoma mucin) with or without low radiosensitising doses of gemcitabine.

METHODS:

Fifty-eight patients with three (2-7) median prior treatments were treated on Arm A (N=29, (90)Y-clivatuzumab tetraxetan, weekly 6.5 mCi/m(2)doses×3, plus gemcitabine, weekly 200 mg/m(2) doses×4 starting 1 week earlier) or Arm B (N=29, (90)Y-clivatuzumab tetraxetan alone, weekly 6.5 mCi/m(2)doses×3), repeating cycles after 4-week delays. Safety was the primary endpoint; efficacy was also evaluated.

RESULTS:

Cytopaenias (predominantly transient thrombocytopenia) were the only significant toxicities. Fifty-three patients (27 Arm A, 26 Arm B, 91% overall) completed ⩾1 full treatment cycles, with 23 (12 Arm A, 11 Arm B; 40%) receiving multiple cycles, including seven (6 Arm A, 1 Arm B; 12%) given 3-9 cycles. Two patients in Arm A had partial responses by RECIST criteria. Kaplan-Meier overall survival (OS) appeared improved in Arm A versus B (hazard ratio [HR] 0.55, 95% CI: 0.29-0.86; P=0.017, log-rank) and the median OS for Arm A versus Arm B increased to 7.9 versus 3.4 months with multiple cycles (HR 0.32, P=0.004), including three patients in Arm A surviving >1 year.

CONCLUSIONS:

Clinical studies of (90)Y-clivatuzumab tetraxetan combined with low-dose gemcitabine appear feasible in metastatic pancreatic cancer patients beyond 2nd line and a Phase III trial of this combination is now underway in this setting.

2014-07-01·mAbs

Antibodies to watch in 2014

作者: Reichert, Janice M

The commercial pipeline of monoclonal antibodies is highly dynamic, with a multitude of transitions occurring during the year as product candidates advance through the clinical phases and onto the market. The data presented here add to that provided in the extensive "Antibodies to watch in 2014" report published in the January/February 2014 issue of mAbs. Recent phase transition data suggest that 2014 may be a banner year for first approvals of antibody therapeutics. As of May 2014, three products, ramucirumab (Cyramza®), siltuximab (Sylvant®) and vedolizumab (Entyvio™), had been granted first approvals in the United States, and four additional antibody therapeutics (secukinumab, dinutuximab, nivolumab, pembrolizumab) are undergoing regulatory review in either the US or the European Union. Other notable events include the start of first Phase 3 studies for seven antibody therapeutics (dupilumab, SA237, etrolizumab, MPDL3280A, bavituximab, clivatuzumab tetraxetan, blinatumomab). Relevant data for these product candidates are summarized, and metrics for antibody therapeutics development are discussed.

2012-11-15·Cancer1区 · 医学

Fractionated radioimmunotherapy with ⁹⁰Y‐clivatuzumab tetraxetan and low‐dose gemcitabine is active in advanced pancreatic cancer

1区 · 医学

Article

作者: Sung, Max W. ; Montero, Alberto J. ; Guarino, Michael J. ; Gulec, Seza A. ; Horne, Heather ; Serafini, Aldo N. ; Ocean, Allyson J. ; Manzone, Timothy ; Pennington, Kenneth L. ; Gold, David V. ; Kauh, John ; Bekaii-Saab, Tanios ; Hall, Nathan ; Sheikh, Arif ; Wegener, William A. ; Goldsmith, Stanley J. ; O'Neil, Bert H. ; Holt, Michael ; Lee, Daniel ; Goldenberg, David M.

Abstract:

BACKGROUND::

It has been demonstrated that the humanized clivatuzumab tetraxetan (hPAM4) antibody targets pancreatic ductal carcinoma selectively. After a trial of radioimmunotherapy that determined the maximum tolerated dose of single‐dose yttrium‐90‐labeled hPAM4 (90Y‐hPAM4) and produced objective responses in patients with advanced pancreatic ductal carcinoma, the authors studied fractionated radioimmunotherapy combined with low‐dose gemcitabine in this disease.

METHODS::

Thirty‐eight previously untreated patients (33 patients with stage IV disease and 5 patients with stage III disease) received gemcitabine 200 mg/m2 weekly for 4 weeks with 90Y‐hPAM4 given weekly in Weeks 2, 3, and 4 (cycle 1), and the same cycle was repeated in 13 patients (cycles 2‐4). In the first part of the study, 19 patients received escalating weekly 90Y doses of 6.5 mCi/m2, 9.0 mCi/m2, 12.0 mCi/m2, and 15.0 mCi/m2. In the second portion, 19 additional patients received weekly doses of 9.0 mCi/m2 or 12.0 mCi/m2.

RESULTS::

Grade 3/4 thrombocytopenia or neutropenia (according to version 3.0 of the National Cancer Institute's Common Terminology Criteria for Adverse Events) developed in 28 of 38 patients after cycle 1 and in all retreated patients; no grade >3 nonhematologic toxicities occurred. Fractionated dosing of cycle 1 allowed almost twice the radiation dose compared with single‐dose radioimmunotherapy. The maximum tolerated dose of 90Y‐hPAM4 was 12.0 mCi/m2 weekly for 3 weeks for cycle 1, with ≤9.0 mCi/m2 weekly for 3 weeks for subsequent cycles, and that dose will be used in future trials. Six patients (16%) had partial responses according to computed tomography‐based Response Evaluation Criteria in Solid Tumors, and 16 patients (42%) had stabilization as their best response (58% disease control). The median overall survival was 7.7 months for all 38 patients, including 11.8 months for those who received repeated cycles (46% [6 of 13 patients] ≥1 year), with improved efficacy at the higher radioimmunotherapy doses.

CONCLUSIONS::

Fractionated radioimmunotherapy with 90Y‐hPAM4 and low‐dose gemcitabine demonstrated promising therapeutic activity and manageable myelosuppression in patients with advanced pancreatic ductal carcinoma. Cancer 2012. © 2012 American Cancer Society.

项与 90Y Clivatuzumab Tetraxetan 相关的新闻（医药）

2026-06-09

·上海丰能数字健康技术研究院

【文献解读075】放射性核素靶向策略在胰腺癌诊疗中的研究进展

——基于《药学进展》2025年综述的深度解读引言：临床痛点与破局之匙胰腺癌，素有“癌王”之称，是恶性程度最高的消化道肿瘤之一。其临床挑战严峻：位置隐蔽，早期无明显症状，导致80%-90%的患者确诊时已属晚期，失去手术机会。5年生存率仅约13%，且对传统放化疗及免疫治疗的反应不佳。诊断层面，常规影像学（如CT、MRI）在区分肿瘤与炎症/纤维化、检测微转移灶方面存在局限；治疗层面，如何实现精准打击并降低对正常组织的损伤是核心难题。2025年9月，《药学进展》期刊发表了一篇题为《放射性核素靶向策略在胰腺癌诊疗中的研究进展》的综述（作者：徐珊珊、李晓阳、洪浩、何健等），系统梳理了核医学如何通过整合功能成像与分子靶向治疗，为突破这些困局提供新思路。本文将基于该综述，结合领域内关键数据与前沿进展，进行深度剖析。一、临床常规与局限：18F-FDG PET/CT的现状1.1 基于“瓦尔堡效应”的经典应用 18F-FDG PET/CT是目前肿瘤显像中最常用的放射性药物之一。其原理基于癌细胞异常活跃的糖代谢（瓦尔堡效应）。超过90%的胰腺导管腺癌（PDAC）因KRAS突变，导致葡萄糖转运体（GLUT1）和己糖激酶Ⅱ过表达，使得肿瘤对FDG的摄取显著高于正常胰腺组织。该技术能提供全身性的分子代谢信息，在以下方面具有重要价值：1）辅助初诊时CT/MRI难以确诊的病灶；2）评估远处转移；3）监测治疗反应及鉴别复发与纤维化。1.2 不可忽视的临床局限然而，18F-FDG PET/CT的特异性仅为65%左右。其主要局限在于无法有效区分PDAC与局灶性慢性胰腺炎，导致假阳性风险。此外，患者的高血糖状态也会显著影响检查的准确性。这些局限性催生了对新型、高特异性放射性示踪剂的迫切需求。二、靶向肿瘤抗原：直击癌细胞的“精准导弹” 近年来，针对肿瘤细胞表面特异性抗原的放射性核素药物研发进展迅速。这些“精准导弹”不仅用于诊断，更在治疗上展现出潜力。下表汇总了文献中提及的主要靶向肿瘤抗原的探针及其研究现状。靶点代表性放射性示踪剂主要进展与临床阶段主要挑战/备注 MUC1 64Cu-DOTA-C595 (诊断), 177Lu/213Bi-C595 (治疗) 90Y-放射性标记抗体联合小剂量化疗的临床研究显示对部分转移性患者可行。研究仍处初级阶段，需优化示踪剂以改善预后。间皮素 64Cu/89Zr/111In-抗MSLN抗体, α核素标记物多种核素标记的抗体在临床前及早期临床中显示优异显像；α核素治疗潜力良好。存在肝生理性摄取，可能干扰腹膜转移评估。需开发小型化抗体或预靶向策略。 PSMA 68Ga/18F-PSMA 68Ga-PSMA在胰腺病变中阳性预测率高于FDG，为PSMA阳性患者带来治疗新希望。临床研究多为单中心、小样本。需更大规模试验验证。 PD-1/PD-L1 64Cu/68Ga/89Zr-抗PD-1/PD-L1抗体在其他癌种中展现良好反应；是评估免疫疗法的重要工具。在胰腺癌中单独使用免疫疗法效果不佳，需开发联合策略的示踪剂。大多研究仍处临床前阶段。 KRAS 131I-ARS-1620 (靶向G12C突变) 在体外和体内试验中能够直接成像并筛选KRAS G12C突变体。 KRAS是胞内蛋白，传统核素载体难以有效结合及递送。需研发穿透性更强的新型药物。笔者认为，靶向肿瘤抗原的策略虽然前景广阔，但其核心挑战在于如何平衡靶点的肿瘤特异性与生理分布、如何克服肿瘤致密间质屏障对药物递送的阻碍。例如，虽然CA19-9是临床最常用的血清标志物，但作为核素靶点，其敏感性和特异性不足，且血液中高水平的抗原会形成“血池”背景，显著降低肿瘤/本底比值。未来的探针设计必须向小型化、高亲和力、药代动力学优化的方向发展。三、靶向肿瘤间质：攻破“纤维化堡垒”的新路径 PDAC的另一显著特征是其富含纤维结缔组织和炎症反应的致密间质，这构成了抵抗治疗的“堡垒”。靶向间质成分已成为创新的诊疗策略。3.1 成纤维细胞活化蛋白：诊断的“明星靶点” 成纤维细胞活化蛋白（FAP）在超过90%的PDAC相关成纤维细胞（CAF）中高表达，而在正常组织中几乎不表达。68Ga-FAPI-04 PET/CT在临床应用中展现出优异性能。关键数据显示，与18F-FDG相比，68Ga-FAPI-04在检测原发肿瘤、淋巴结及远处转移方面具有更高的敏感性和图像对比度，在临床分期上优势明显。尽管其治疗应用（如90Y-FAPI-04）报道尚少，但无疑是当前胰腺癌诊疗一体化研究中的热点。3.2 整合素αvβ6与纤维连接蛋白：临床前潜力初显整合素αvβ6在PDAC中的阳性率超过95%。68Ga标记的靶向肽和177Lu-DOTA-胱氨酸结肽在临床前模型中显示出高亲和力和特异性，证明了其在成像与治疗中的双重潜力。靶向纤维连接蛋白（FN）剪接区域的纳米体64Cu-NJB2，则能在小鼠模型中检测到早期胰腺上皮内瘤变，为极早期诊断带来了曙光。然而，这些探针的临床转化仍需大型、确证性的Ⅲ期临床试验数据支持。四、核心要点与未来展望诊疗一体化是核心方向：放射性核素靶向策略的核心价值在于将诊断（Diagnostics）与治疗（Therapy）无缝整合，实现真正的精准医疗。多种探针（如靶向MSLN、FAP的探针）已初步展现出“一药两用”的潜力。靶点选择决定应用场景：FAP、整合素αvβ6等间质靶点因其穿透性强，在早期诊断和分期中可能更具优势；而MUC1、MSLN等肿瘤细胞抗原则可能更适合作为治疗载体的靶向选择。临床转化仍是巨大瓶颈：绝大多数有前景的探针仍停留在临床前或早期（I/II期）临床阶段。从实验室到临床，需跨越药代动力学优化、毒性评估、生产标准化等多重障碍。未来突破在于“组合”与“智能”：未来的研究应聚焦于：a) 探针设计革新，如开发小型化、双特异性分子以提升穿透力与亲和力；b) 联合治疗策略，如探索放射增敏剂与核素治疗、化疗、免疫治疗的协同方案；c) 智能化技术赋能，利用人工智能预测最佳给药剂量，并基于患者的基因分型（如KRAS突变状态）定制个体化诊疗方案。综上所述，尽管前路挑战重重，但放射性核素靶向策略无疑为攻克胰腺癌这一“癌王”提供了极具希望的新武器。它不仅是影像技术的革新，更是治疗范式的演进。随着新型分子靶点探针的持续开发、多学科协作的深化以及临床转化步伐的加快，胰腺癌诊疗的精准化与个性化突破正逐渐从愿景走向现实。参考文献： [1] Stoop T F, et al. Pancreatic cancer. Lancet, 2025. [2] Siegel R L, et al. Cancer statistics, 2024. CA Cancer J Clin, 2024. [3] Hu Z I, O’Reilly E M. Therapeutic developments in pancreatic cancer. Nat Rev Gastroenterol Hepatol, 2024. [4] Wagle N S, et al. Cancer treatment and survivorship statistics, 2025. CA Cancer J Clin, 2025. [5] Jhala N, et al. Molecular tests in pancreatic cancer. J Natl Compr Canc Netw, 2024. [6] Ying H, et al. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev, 2025. [7] Hu S, et al. (18)F-FDG-PET/CT findings in pancreatic metastasis. Radiol Med, 2015. [8] Ferdinandus J, et al. Theranostics in oncology. Eur J Radiol, 2021. [9] Hu M, et al. Advances in preclinical research of theranostic radiopharmaceuticals. ACS Appl Mater Interfaces, 2025. [10] Bidkar A P, et al. Treatment of prostate cancer with CD46-targeted 225Ac alpha particle radioimmunotherapy. Clin Cancer Res, 2023. [11] Wang J, et al. Preliminary study on the ability of the machine learning models based on (18)F-FDG PET/CT... Eur J Radiol, 2024. [12] Carlson D M, et al. Baseline characteristics and use of pretherapeutic 18F-fluorodeoxyglucose-PET for pancreatic cancer. J Am Coll Surg, 2024. [13] Suh H, et al. Mucins in pancreatic cancer. Am J Cancer Res, 2017. [14] Hull A, et al. Development of [225Ac]Ac-DOTA-C595 as radioimmunotherapy of pancreatic cancer. EJNMMI Radiopharm Chem, 2023. [15] Picozzi V J, et al. (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine. Eur J Cancer, 2015. [16] Liu D, et al. Mesothelin-associated anti-senescence through P53 in pancreatic ductal adenocarcinoma. Cancers (Basel), 2025. [17] Kobayashi K, et al. A novel PET imaging using 64Cu-labeled monoclonal antibody against mesothelin. J Immunol Res, 2015. [18] Lu Z, et al. Preclinical evaluation of 89Zr/177Lu-labeled amatuximab for theranostic application in PDAC. Int J Pharm, 2024. [19] Wang X, et al. Construction and preclinical evaluation of 211At labeled anti-mesothelin antibodies. J Radiat Res, 2020. [20] Hung Y H, et al. Neuron-derived neurotensin promotes pancreatic cancer invasiveness and gemcitabine resistance. Am J Cancer Res, 2024. [21] Hodolic M, et al. Safety and tolerability of 68Ga-NT-20.3 in patients with PDAC. Eur J Nucl Med Mol Imaging, 2021. [22] Pabst K M, et al. Detection of tumour heterogeneity... on [68Ga]Ga-FAPI-46 and 2-[18F]FDG PET/CT. Eur J Nucl Med Mol Imaging, 2024. [23] Puik J R, et al. 18F-prostate-specific membrane antigen PET/CT imaging for potentially resectable pancreatic cancer. Cancer Imaging, 2025. [24] Aziz M H, et al. Overexpression of the adhesion signaling pathway is linked to short-term survival in PDAC. Pancreatology, 2024. [25] Tsang K Y, et al. Development and characterization of an anti-cancer monoclonal antibody for treatment of human carcinomas. Cancers (Basel), 2022. [26] Schoffelen R, et al. Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer. Br J Cancer, 2013. [27] Hitchen N, et al. Recent advances in therapeutic targeting of the KRAS pathway in cancer. Pharmacol Ther, 2025. [28] Suyal C, et al. Structure-activity relationships of KRAS-G12D inhibitors for pancreatic cancer. Drug Discov Today, 2025. [29] Zhang Z, et al. Development and preclinical evaluation of radiolabeled covalent G12C-specific inhibitors. Mol Pharm, 2021. [30] Chen M H, et al. Cancer cell-intrinsic PD-1. Biomed Pharmacother, 2023. [31] Daunke T, et al. Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of PDAC. Front Immunol, 2023. [32] van de Donk P P, et al. Molecular imaging to support cancer immunotherapy. J Immunother Cancer, 2022. [33] Burvenich I J G, et al. Molecular imaging of T cell co-regulator factor B7-H3 with 89Zr-DS-5573a. Theranostics, 2018. [34] Luo G P, et al. Roles of CA19-9 in pancreatic cancer. Biochim Biophys Acta Rev Cancer, 2021. [35] Poty S, et al. 89Zr-PET imaging of DNA double-strand breaks... in a mouse model of PDAC. Theranostics, 2020. [36] Zhu J, et al. In vivo PET imaging of EGFR expression: an overview of radiolabeled EGFR TKIs. Curr Top Med Chem, 2022. [37] Homedan A, et al. Protein-based radiopharmaceuticals that target fibroblast activation protein alpha. EJNMMI Radiopharm Chem, 2025. [38] Ganguly T, et al. Preclinical evaluation of 68Ga- and 177Lu-labeled integrin αvβ6-targeting radiotheranostic peptides. J Nucl Med, 2023. [39] Sachindra S, et al. SPECT/CT imaging, biodistribution and radiation dosimetry of a 177Lu-DOTA-Integrin αvβ6 cystine knot peptide. Front Oncol, 2021. [40] Hu D Y, et al. Stromal fibronectin expression in patients with resected PDAC. World J Surg Oncol, 2019. [41] Jailkhani N, et al. Noninvasive imaging of tumor progression, metastasis, and fibrosis using a nanobody targeting the extracellular matrix. Proc Natl Acad Sci USA, 2019. [42] 黄敏. 靶向肿瘤代谢的新药研发：挑战与机遇. 药学进展, 2024. [43] 李顺尧, 等. 靶向肿瘤代谢酶小分子药物研究进展. 药学进展, 2024.

100 项与 90Y Clivatuzumab Tetraxetan 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	90Y Clivatuzumab Tetraxetan	-	DB15368

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
转移性胰腺癌	临床3期	美国	Gilead Sciences, Inc.	2013-12-01
转移性胰腺癌	临床3期	奥地利	Gilead Sciences, Inc.	2013-12-01
转移性胰腺癌	临床3期	比利时	Gilead Sciences, Inc.	2013-12-01
转移性胰腺癌	临床3期	加拿大	Gilead Sciences, Inc.	2013-12-01
转移性胰腺癌	临床3期	法国	Gilead Sciences, Inc.	2013-12-01
转移性胰腺癌	临床3期	以色列	Gilead Sciences, Inc.	2013-12-01
转移性胰腺癌	临床3期	波兰	Gilead Sciences, Inc.	2013-12-01
转移性胰腺癌	临床3期	西班牙	Gilead Sciences, Inc.	2013-12-01
转移性胰腺腺癌	临床3期	美国	Gilead Sciences, Inc.	2013-12-01
转移性胰腺腺癌	临床3期	奥地利	Gilead Sciences, Inc.	2013-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01956812 (GlobeNewswire) 人工标引	临床3期	胰腺癌	-	Gemcitabine+yttrium-90-labeled (90Y) clivatuzumab tetraxetan	衊鹹選繭夢壓壓繭選廠(憲齋壓夢糧衊齋鑰膚選) = the treatment arm of 90Y-clivatuzumab tetraxetan combined with low-dose gemcitabine and best supportive care did not demonstrate a sufficient improvement in OS as compared to placebo plus low-dose gemcitabine and best supportive care. 鏇簾獵艱淵廠簾醖簾鹹 (構膚願鬱壓鑰網膚觸鏇 )	不佳	2016-03-14
				Gemcitabine+Placebo
NCT01510561 (Pubmed \| Eur J Cancer)	临床1期	转移性胰腺癌	53	(90)Y-clivatuzumab tetraxetan + gemcitabine	製蓋鹹簾觸壓壓蓋願築(鹽鑰醖網淵積獵糧衊壓) = 製構憲蓋衊襯膚鬱選築膚廠襯廠簾鏇襯願廠窪 (艱鏇蓋製醖築蓋簾簾積 )	-	2015-09-01
				(90)Y-clivatuzumab tetraxetan alone	製蓋鹹簾觸壓壓蓋願築(鹽鑰醖網淵積獵糧衊壓) = 繭廠願獵築醖觸餘鑰顧膚廠襯廠簾鏇襯願廠窪 (艱鏇蓋製醖築蓋簾簾積 )
NCT01510561 (ASCO2014)	临床1期	转移性胰腺癌	58	Arm A (GEM + <sup>90</sup>Y-clivatuzumab tetraxetan)	網觸淵壓鏇觸艱襯夢築(餘餘繭網獵積壓鑰網醖) = 鬱夢憲鬱膚淵選蓋鑰憲遞顧衊壓選鹽鏇繭簾選 (鏇糧衊蓋簾積遞鹽蓋鹽 )	-	2014-05-20
				Arm B (<sup>90</sup>Y-clivatuzumab tetraxetan alone)	網觸淵壓鏇觸艱襯夢築(餘餘繭網獵積壓鑰網醖) = 蓋鬱糧齋齋選壓醖顧鹽遞顧衊壓選鹽鏇繭簾選 (鏇糧衊蓋簾積遞鹽蓋鹽 )
ASCO_GI2012	临床1/2期	胰腺癌一线	100	90Y-hPAM4	網鹹獵顧製觸觸鑰顧糧(繭鹽顧淵顧製蓋簾蓋願) = 選構襯繭鏇蓋夢膚餘網製築蓋蓋窪夢糧廠壓鏇 (鏇膚築繭憲構齋鬱範衊 )	-	2012-02-01
ASCO_GI2011	临床1/2期	胰腺癌	42	Clivatuzumab tetraxetan	鹽觸衊齋齋鏇淵齋鬱糧(蓋衊夢窪獵範構製窪觸) = improved 願鏇廠醖簾淵簾艱淵築 (鹽蓋艱廠繭糧遞範積膚 )	-	2011-02-01
				Gemcitabine
ASCO2010	临床1/2期	胰腺癌	-	Clivatuzumab tetraxetan	餘願鑰製遞遞艱鬱餘夢(鬱夢窪鹽觸簾廠構襯憲) = 觸壓鹹構襯願築網選範繭積範製廠艱淵構憲繭 (鹹齋鑰顧簾蓋壓膚網獵 ) 更多	-	2010-05-20